Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (14812)	10/2/2000 7:19:28 AM
From: BostonView	Read Replies (1) \| Respond to of 17367

William Muggia, Portfolio Manager, Growth Touchstone Emerging Growth Fund was on CNBC this morning (before 7 am) and included XOMA as a hot pick. He said it was cheap relative to it's peers, noted its pipeline, and highlighted the partnership with Genetech (DNA) on AntiCD11a. BV

To: aknahow who wrote (14812)	10/9/2000 11:36:49 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, it has been quite awhile since publication of the Meningo. trial results in the Lancet. With all due respect to the Meningitis foundation, do you see where they are helping the kids with gram neg Meningo. in Mich. get Neuprex???? Are they are countering these articles one by one??? BTW, what is the OFFICIAL stance of the Meningitis foundation in regard to Neuprex NOW THAT THEY HAVE THE PUBLICATION????? YOU KNOW, THE PUBLICATION EVERYONE WAS WAITING TO SEE????? Yeah, right.